Skip to main content
This R&D Website is for US Healthcare Professionals Only

Pipeline

Explore Our Pipeline

AbbVie has been involved in oncology research, discovery and development for more than 20 years. Our team members combine their deep understanding of cancer with state-of-the-art technologies to research, validate and target specific molecular pathways. This allows us to discover and develop innovative therapies that aim to disturb the natural progression of cancer cells.

Investigational drugs mentioned are for use in clinical studies only, and may be studied alone or in combination with drugs for indications that have not been approved by the FDA. Approved drugs mentioned are also being studied for uses for which they are not approved. Safety and efficacy have not been established for any of these drugs for the uses being studied.

AbbVie in no way intends to recommend or imply that these drugs should be used for unapproved uses.

View Cancer Type

Hematologic Malignancies

Phase 1

Phase 2

Phase 3

Venetoclax (ABT-199/GDC-0199) BCL-2 INHIBITOR

Overview

Venetoclax (ABT-199/GDC-0199) is a selective, orally bioavailable small-molecule BCL-2 inhibitor.1

Proposed Mechanism of Disease

The BCL-2 protein binds and sequesters proapoptotic proteins, limiting their ability to initiate apoptosis. Venetoclax is designed to bind to BCL-2, preventing it from binding to proapoptotic proteins and thereby restoring the cell's ability to undergo apoptosis.1

Development

Venetoclax was approved in April 2016 under accelerated approval conditions for the treatment of patients with CLL with 17p deletion, as detected by an FDA-approved test, who have received at least one prior therapy. AbbVie and Genentech continue to investigate venetoclax in ongoing phase 3 and phase 2 clinical trials for the treatment of CLL, as well as a variety of other cancers, including acute myeloid leukemia (AML), multiple myeloma (MM), subtypes of non-Hodgkin's Lymphoma (NHL) [Mantle Cell Lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)] and Acute Lymphoblastic Leukemia (ALL).

Clinical Trials

View select clinical trials with venetoclax now. To view a full list of clinical trials in which venetoclax is being investigated, please visit ClinicalTrials.gov.

Venetoclax (ABT-199/GDC-0199) is an approved drug being studied for unapproved uses. Safety and efficacy have not been established for these unapproved uses.

VENETOCLAX MOD and PROPOSED MOA

See the role of the BCL-2 pathway in evading apoptosis and promoting tumor survival. Learn about venetoclax and its role in BCL-2 inhibition.

Close
Chronic Lymphocytic Leukemia (CLL)
PH 3
Multiple Myeloma (MM)
PH 3
Acute Myeloid Leukemia (AML)
PH 3
Non-Hodgkin's Lymphoma (NHL)
PH 3
Myelodysplastic Syndromes (MDS)
PH 2

Navitoclax (ABT-263) BCL-XL/BCL-2 Inhibitor

Overview

Navitoclax (ABT-263) is an orally active inhibitor of the BCL-XL and BCL-2 proteins.2

Proposed Mechanism of Disease

Inhibiting the JAK2 signaling network at both the initiating stage (JAK2) and the effector stage (BCL-XL/BCL-2) may reduce tumor burden while minimizing resistance to JAK-2 inhibition.3,4

Development

Navitoclax is in phase 2 development for myelofibrosis in combination with ruxolitinib.

Clinical Trials

View select clinical trials with navitoclax now. To view a full list of clinical trials in which navitoclax is being investigated, please visit ClinicalTrials.gov.

Navitoclax (ABT-263) is an investigational drug for clinical study only. Safety and efficacy have not been established.

Close
Myelofibrosis (MF)
PH 2

ABBV-621 TRAIL Agonist

Overview

ABBV-621 is a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) agonist.

Development

ABBV-621 is being studied in a phase 1 clinical trial in patients with previously treated solid tumors and hematologic malignancies.

Clinical Trials

View select clinical trials with ABBV-621 now. To view a full list of clinical trials in which venetoclax is being investigated, please visit ClinicalTrials.gov.

ABBV-621 is an investigational drug for clinical study only. Safety and efficacy have not been established.

Close
Non-Hodgkin's Lymphoma (NHL)
PH 1
Acute Myeloid Leukemia (AML)
PH 1

Mivebresib (ABBV-075) BET Inhibitor

Overview

Mivebresib (ABBV-075) is an orally active small-molecule Bromodomain (BRD) and Extra-Terminal motif (BET) inhibitor.5

Development

Mivebresib is being studied in a phase 1 clinical trial in patients with advanced hematologic malignancies, prostate cancer, and other solid tumors.

Clinical Trials

View select clinical trials with Mivebresib now. To view a full list of clinical trials in which Mivebresib is being investigated, please visit ClinicalTrials.gov.

Mivebresib (ABBV-075) is an investigational drug for clinical study only. Safety and efficacy have not been established.

Close
Acute Myeloid Leukemia (AML)
PH 1
Multiple Myeloma (MM)
PH 1
Non-Hodgkin's Lymphoma (NHL)
PH 1

Lung Cancer

Phase 1

Phase 2

Phase 3

Veliparib (ABT-888) PARP Inhibitor

Overview

Veliparib (ABT-888) is an oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor that AbbVie is evaluating in multiple tumor types.6,7

Proposed Mechanism of Action

Proteins of the PARP family are naturally occurring enzymes in human cells that are critical to the repair of single-strand DNA breaks.6,7 While this is a useful process to maintain the integrity of healthy cells, the same process can also repair chemotherapy-induced DNA damage in cancer cells that may have limited capacity for repairing double-strand DNA breaks.7,8 Veliparib is designed to inhibit PARP1 and PARP2, potentially leading to the accumulation of single-strand and double-strand DNA breaks in tumor cells that may have limited capacity for DNA repair, which results in chromosomal instability, cell cycle arrest, and subsequent apoptosis.6,7,9

Development

Veliparib is being developed in settings where it can be combined with common DNA-damaging therapies like chemotherapy or radiation.6,7,10-13 It is in clinical trials for the treatment of patients with BRCA-deficient breast cancer, ovarian cancer, and lung cancer, as well as a number of other cancer types.

Clinical Trials

View select clinical trials with veliparib now. To view a full list of clinical trials in which veliparib is being investigated, please visit ClinicalTrials.gov.

Veliparib (ABT-888) is an investigational drug that is for clinical study only. Safety and efficacy have not been established.

MOD and Proposed MOA

See how Veliparib may play a role in dual PARP inhibition.

Close
Non-Squamous Non-Small Cell Lung Cancer (NsqNSCLC)
PH 3
Small Cell Lung Cancer (SCLC)
PH 2

Rovalpituzumab Tesirine (Rova-T) DLL3-Targeted ADC

Overview

Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate (ADC) comprising a humanized DLL3-specific IgG1 monoclonal antibody conjugated to a pyrrolobenzodiazepine dimer (PBD), a sequence-selective DNA cross-linking agent.14

Proposed Mechanism of Action

DLL3 is expressed at high levels on the cell surface of >80% of small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) tumors, with little to no expression in normal tissues.14 In preclinical models, Rova-T has been shown to specifically bind to DLL3, followed by internalization and trafficking to late endosomes. The cytotoxin (PBD) is released, ultimately leading to apoptosis of the tumor cell with minimal effect on normal tissue.14

Development

Rova-T is currently being investigated in phase 1 through phase 3 trials for the treatment of SCLC and other advanced solid tumors. Rova-T has received orphan drug designation from the FDA for treatment of SCLC.

Clinical Trials

View select clinical trials with Rova-T now. To view a full list of clinical trials in which Rova-T is being investigated, please visit ClinicalTrials.gov.

Rovalpituzumab Tesirine (Rova-T) is an investigational drug for clinical study only. Safety and efficacy have not been established.

MOD and Proposed MOA

Learn more about rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate.

Close
Small Cell Lung Cancer (SCLC)
PH 3

Telisotuzumab Vedotin (Teliso-V; ABBV-399) cMet-Targeted ADC

Overview

Telisotuzumab vedotin (Teliso-V; ABBV-399) is a cMet-targeted antibody-drug conjugate (ADC).

Proposed Mechanism of Action

In preclinical models, Teliso-V delivers a potent cytotoxin to cMet-overexpressing tumor cells enabling cell killing regardless of reliance on MET signaling.15

Development

Teliso-V is being studied in a phase 2 clinical trial in patients with non-small cell lung cancer (NSCLC) and in a phase 1 trial in patients with solid tumors.

Clinical Trials

View select clinical trials with telisotuzumab vedotin now. To view a full list of clinical trials in which telisotuzumab vedotin is being investigated, please visit ClinicalTrials.gov.

Telisotuzumab vedotin (Teliso-V; ABBV-399) is an investigational drug for clinical study only. Safety and efficacy have not been established.

Close
Non-Small Cell Lung Cancer (NSCLC)
PH 2

Brain Cancer

Phase 1

Phase 2

Phase 3

Depatuxizumab Mafodotin (Depatux-M; ABT-414) Epidermal Growth Factor Receptor (EGFR)-Targeted ADC

Overview

Depatuxizumab mafodotin (Depatux-M; ABT-414) is an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC).16

Proposed Mechanism of Action

Depatux-M is an antibody-drug conjugate (ADC) that combines the cytotoxin monomethyl auristatin F (MMAF) with a monoclonal antibody targeting a unique epitope of the EGFR that exhibits minimal reactivity to EGFR in normal tissues.16 As an ADC, Depatux-M is designed to remain stable in the bloodstream, potentially releasing the potent cytotoxin only inside targeted cancer cells. Studies are being conducted to determine if this approach can potentially reduce the toxic side effects of traditional chemotherapy while enhancing antitumor activity.

Development

Depatux-M is being studied in a phase 3 trial in patients with newly diagnosed GBM. GBM is the most common and most aggressive malignant primary brain tumor.

Clinical Trials

View select clinical trials with depatuxizumab mafodotin now. To view a full list of clinical trials in which depatuxizumab mafodotin is being investigated, please visit ClinicalTrials.gov.

Depatuxizumab mafodotin (Depatux-M; ABT-414) is an investigational drug that is for clinical study only. Safety and efficacy have not been established.

Depatuxizumab Mafodotin (Depatux‑M) MOD and Proposed MOA

Learn about EGFR amplification and mutation.

Close
Glioblastoma Multiforme (GBM)
PH 3

Breast Cancer

Phase 1

Phase 2

Phase 3

Veliparib (ABT-888) PARP Inhibitor

Overview

Veliparib (ABT-888) is an oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor that AbbVie is evaluating in multiple tumor types.6,7

Proposed Mechanism of Action

Proteins of the PARP family are naturally occurring enzymes in human cells that are critical to the repair of single-strand DNA breaks.6,7 While this is a useful process to maintain the integrity of healthy cells, the same process can also repair chemotherapy-induced DNA damage in cancer cells that may have limited capacity for repairing double-strand DNA breaks.7,8 Veliparib is designed to inhibit PARP1 and PARP2, potentially leading to the accumulation of single-strand and double-strand DNA breaks in tumor cells that may have limited capacity for DNA repair, which results in chromosomal instability, cell cycle arrest, and subsequent apoptosis.6,7,9

Development

Veliparib is being developed in settings where it can be combined with common DNA-damaging therapies like chemotherapy or radiation.6,7,10-13 It is in clinical trials for the treatment of patients with BRCA-deficient breast cancer, ovarian cancer, and lung cancer, as well as a number of other cancer types.

Clinical Trials

View select clinical trials with veliparib now. To view a full list of clinical trials in which veliparib is being investigated, please visit ClinicalTrials.gov.

Veliparib (ABT-888) is an investigational drug that is for clinical study only. Safety and efficacy have not been established.

MOD and Proposed MOA

See how veliparib may play a role in dual PARP inhibition.

Close
BRCA-Deficient Breast Cancer
PH 3

Solid Tumors

Phase 1

Phase 2

Phase 3

ABBV-621 TRAIL Agonist

Overview

ABBV-621 is a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) agonist.

Development

ABBV-621 is being studied in a phase 1 clinical trial in patients with previously treated solid tumors and hematologic malignancies.

Clinical Trials

View select clinical trials with ABBV-621 now. To view a full list of clinical trials in which ABBV-621 is being investigated, please visit ClinicalTrials.gov.

ABBV-621 is an investigational drug for clinical study only. Safety and efficacy have not been established.

Close
Previously Treated Solid Tumors
PH 1

Veliparib (ABT-888) PARP Inhibitor

Overview

Veliparib (ABT-888) is an oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor that AbbVie is evaluating in multiple tumor types.6,7

Proposed Mechanism of Action

Proteins of the PARP family are naturally occurring enzymes in human cells that are critical to the repair of single-strand DNA breaks.6,7 While this is a useful process to maintain the integrity of healthy cells, the same process can also repair chemotherapy-induced DNA damage in cancer cells that may have limited capacity for repairing double-strand DNA breaks.7,8 Veliparib is designed to inhibit PARP1 and PARP2, potentially leading to the accumulation of single-strand and double-strand DNA breaks in tumor cells that may have limited capacity for DNA repair, which results in chromosomal instability, cell cycle arrest, and subsequent apoptosis.6,7,9

Development

Veliparib is being developed in settings where it can be combined with common DNA-damaging therapies like chemotherapy or radiation.6,7,10-13 It is in clinical trials for the treatment of patients with BRCA-deficient breast cancer, ovarian cancer, and lung cancer, as well as a number of other cancer types.

Clinical Trials

View select clinical trials with veliparib now. To view a full list of clinical trials in which veliparib is being investigated, please visit ClinicalTrials.gov.

Veliparib (ABT-888) is an investigational drug that is for clinical study only. Safety and efficacy have not been established.

MOD and PROPOSED MOA

See how veliparib may play a role in dual PARP inhibition.

Close
Ovarian Cancer
PH 3

Mivebresib (ABBV-075) BET Inhibitor

Overview

Mivebresib (ABBV-075) is an orally active small-molecule Bromodomain (BRD) and Extra-Terminal motif (BET) inhibitor.5

Development

Mivebresib is being studied in a phase 1 clinical trial in patients with advanced hematologic malignancies, prostate cancer, and other solid tumors.

Clinical Trials

View select clinical trials with mivebresib now. To view a full list of clinical trials in which mivebresib is being investigated, please visit ClinicalTrials.gov.

Mivebresib (ABBV-075) is an investigational drug for clinical study only. Safety and efficacy have not been established.

Close
Prostate Cancer
PH 1
Advanced Cancers
PH 1

Telisotuzumab Vedotin (Teliso-V; ABBV-399) cMet-Targeted ADC

Overview

Telisotuzumab vedotin (Teliso-V; ABBV-399) is a cMet-targeted antibody-drug conjugate (ADC).

Proposed Mechanism of Action

In preclinical models, Teliso-V delivers a potent cytotoxin to cMet-overexpressing tumor cells enabling cell killing regardless of reliance on MET signaling.15

Development

Teliso-V is being studied in a phase 2 clinical trial in patients with non-small cell lung cancer (NSCLC) and in a phase 1 trial in patients with solid tumors.

Clinical Trials

View select clinical trials with telisotuzumab vedotin now. To view a full list of clinical trials in which telisotuzumab vedotin is being investigated, please visit ClinicalTrials.gov.

Telisotuzumab vedotin (Teliso-V; ABBV-399) is an investigational drug for clinical study only. Safety and efficacy have not been established.

Close
Solid Tumors
PH 1

ABBV-085 LRRC15-Targeted ADC

Overview

ABBV-085 is a tumor antigen LRRC15-targeted antibody-drug conjugate (ADC).

Proposed Mechanism of Action

LRRC15 is frequently overexpressed in multiple tumor types.17 As an ADC, ABBV-085 is designed to remain stable in the bloodstream, potentially releasing the potent cytotoxin only inside targeted cancer cells.

Development

ABBV-085 is being studied in a phase 1 clinical trial in patients with advanced solid tumors.

Clinical Trials

To view a full list of clinical trials in which ABBV-085 is being investigated, please visit ClinicalTrials.gov.

ABBV-085 is an investigational drug for clinical study only. Safety and efficacy have not been established.

Close
Advanced Solid Tumors
PH 1

ABBV-176 PRLR-Targeted ADC

Overview

ABBV-176 is a Prolactin Receptor (PRLR)-targeted antibody-drug conjugate (ADC).

Development

ABBV-176 is being studied in a phase 1 clinical trial in patients with advanced solid tumors likely to express prolactin receptor.

Clinical Trials

To view a full list of clinical trials in which ABBV-176 is being investigated, please visit ClinicalTrials.gov.

ABBV-176 is an investigational drug for clinical study only. Safety and efficacy have not been established.

Close
Advanced Solid Tumors
PH 1

ABBV-321 EGFR-Targeted ADC

Overview

ABBV-321 is an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC).

Proposed Mechanism of Action

ABBV-321 is our third-generation EGFR ADC that has three important distinctions from ABT-414. First, it contains an affinity-matured antibody (ABT-806 AM1) with a higher affinity for EGFR. Second and third, it utilizes a different linker that attaches a highly potent cytotoxic agent called a pyrrolobenzodiazepine (PBD) dimer with a fixed DAR of 2.0. PBDs are considered more potent than the auristaten conjugates. ABBV-321 is thought to remain stable in the bloodstream, potentially releasing the potent chemotherapy agent only inside targeted cancer cells. Studies are being conducted to determine if this approach could help reduce the toxic side effects of traditional chemotherapy while potentially enhancing antitumor activity.

Development

Being developed by AbbVie researchers, ABBV-321 is currently being investigated in a phase 1 study for the treatment of patients with advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR) or its ligands.

Clinical Trials

To view a full list of clinical trials in which ABBV-321 is being investigated, please visit ClinicalTrials.gov.

ABBV-321 is an investigational drug for clinical study only. Safety and efficacy have not been established.

Close
Advanced Solid Tumors
PH 1

Rovalpituzumab Tesirine (Rova-T) DLL3-Targeted ADC

Overview

Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate (ADC) comprising a humanized DLL3-specific IgG1 monoclonal antibody conjugated to a pyrrolobenzodiazepine dimer (PBD), a sequence-selective DNA cross-linking agent.14

Proposed Mechanism of Action

DLL3 is expressed at high levels on the cell surface of >80% of small cell lung cancer (SCLC) tumors, with little to no expression in normal tissues.14 In preclinical models, rovalpituzumab tesirine has been shown to specifically bind to DLL3, followed by internalization and trafficking to late endosomes. The cytotoxin (PBD) is released, ultimately leading to apoptosis of the tumor cell with minimal effect on normal tissue.14

Development

Rova-T is currently being investigated in phase 1 through phase 3 trials for the treatment of SCLC and other advanced solid tumors. Rova-T has received orphan drug designation from the FDA for treatment of SCLC.

Rovalpituzumab tesirine (Rova-T) is an investigational drug for clinical study only. Safety and efficacy have not been established.

MOD and Proposed MOA

Learn more about rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate.

Close
Advanced Solid Tumors
PH 1

SC-003

Overview

SC-003 is an antibody-drug conjugate comprising a monoclonal antibody linked to a potent chemotherapy.

Development

SC-003 is being studied in a phase1a/1b clinical trial in patients with platinum-resistant/refractory ovarian cancer.

Clinical Trials

To view a full list of clinical trials in which SC-003 is being investigated, please visit ClinicalTrials.gov.

SC-003 is an investigational drug for clinical study only. Safety and efficacy have not been established.

Close
Platinum-Resistant/Refractory Ovarian Cancer
PH 1

SC-004

Overview

SC-004 is an antibody-drug conjugate.

Development

SC-004 is being studied in a phase 1 clinical trial in patients with high-grade serous ovarian epithelial cancer or metastatic or advanced endometrial carcinoma previously treated with at least 1 platinum-based chemotherapeutic regimen.

Clinical Trials

To view a full list of clinical trials in which SC-004 is being investigated, please visit ClinicalTrials.gov.

SC-004 is an investigational drug for clinical study only. Safety and efficacy have not been established.

Close
Ovarian/Endometrial Cancer
PH 1

SC-006

Overview

SC-006 is an antibody-drug conjugate.

Development

SC-006 is being studied in a phase 1 clinical trial in patients with advanced metastatic colorectal cancer.

Clinical Trials

To view a full list of clinical trials in which SC-006 is being investigated, please visit ClinicalTrials.gov.

SC-006 is an investigational drug for clinical study only. Safety and efficacy have not been established.

Close
Colorectal Cancer
PH 1

ABT-165 DLL4- and VEGF-Targeted Dual Variable Domain (DVD) Immunoglobulin (Bispecific Antibody)

Overview

ABT-165 is a dual variable domain (DVD) immunoglobulin (bispecific antibody) that inhibits both DLL4 and VEGF.18

Development

ABT-165 is being studied in phase 1 trials for the treatment of patients with advanced solid tumors.

Clinical Trials

View select clinical trials with ABT-165 now. To view a full list of clinical trials in which ABT-165 is being investigated, please visit ClinicalTrials.gov.

ABT-165 is an investigational drug for clinical study only. Safety and efficacy have not been established.

Close
Solid Tumors
PH 1

ABBV-428 I-O Bispecific Protein

Overview

ABBV-428 is an immuno-oncology (I-O) bispecific protein.

Development

ABBV-428 is being studied in phase 1 trials for the treatment of solid tumors.

Clinical Trials

To view a full list of clinical trials in which ABBV-428 is being investigated, please visit ClinicalTrials.gov.

ABBV-428 is an investigational drug for clinical study only. Safety and efficacy have not been established.

Close
Advanced Solid Tumors
PH 1

ABBV-181 I-O Monoclonal Antibody (mAb)

Overview

ABBV-181 is an immuno-oncology (I-O) monoclonal antibody.

Development

ABBV-181 is being studied in phase 1 trials for the treatment of solid tumors.

Clinical Trials

To view a full list of clinical trials in which ABBV-181 is being investigated, please visit ClinicalTrials.gov.

ABBV-181 is an investigational drug for clinical study only. Safety and efficacy have not been established.

Close
Advanced Solid Tumors
PH 1

ABBV-368 I-O Monoclonal Antibody (mAb)

Overview

ABBV-368 is an immuno-oncology (I-O) monoclonal antibody.

Development

ABBV-368 is being studied in phase 1 trials for the treatment of solid tumors.

Clinical Trials

To view a full list of clinical trials in which ABBV-368 is being investigated, please visit ClinicalTrials.gov.

ABBV-368 is an investigational drug for clinical study only. Safety and efficacy have not been established.

Close
Advanced Solid Tumors
PH 1

ABBV-927 I-O Monoclonal Antibody (mAb)

Overview

ABBV-927 is an immuno-oncology (I-O) monoclonal antibody.

Development

ABBV-927 is being studied in phase 1 trials for the treatment of solid tumors.

Clinical Trials

To view a full list of clinical trials in which ABBV-927 is being investigated, please visit ClinicalTrials.gov.

ABBV-927 is an investigational drug for clinical study only. Safety and Efficacy have not been established.

Close
Advanced Solid Tumors
PH 1

References

  1. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202-208.
  2. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421-3428.
  3. Waibel M, Solomon VS, Knight DA, et al. Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Rep. 2013;5(4):1047-1059.
  4. Zhang M, Mathews Griner LA, Ju W, et al. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2–dependent adult T-cell leukemia. Proc Natl Acad Sci U S A. 2015;112(40):12480-12485.
  5. McDaniel KF, Wang L, Soltwedel T, et al. Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl) ethanesulfonamide (ABBV-075/Mivebresib), a potent and orally available bromodomain and extraterminal domain (BET) family bromodomain inhibitor. J Med Chem. 2017;60(20):8369-8384.
  6. Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13(9):2728-2737.
  7. Palma JP, Wang YC, Rodriguez LE, et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res. 2009;15(23):7277-7290.
  8. Anders CK, Winer EP, Ford JM, et al. Poly(ADP-ribose) polymerase inhibition: “targeted” therapy for triple-negative breast cancer. Clin Cancer Res. 2010;16(19):4702-4710.
  9. Plummer ER, Calvert H. Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy. Clin Cancer Res. 2007;13(21):6252-6256.
  10. Owonikoko TK, Zhang G, Deng X, et al. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med. 2014;3(6):1579-1594.
  11. Cheng H, Zhang Z, Borczuk A, et al. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis. 2013;34(4):739-749.
  12. Kummar S, Wade JL, Oza AM, et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Invest New Drugs. 2016 Mar 21. [Epub ahead of print]
  13. Reiss KA, Herman JM, Zahurak M, et al. A phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis. Clin Cancer Res. 2015;21(1):68-76.
  14. Saunders LR, Bankovich AJ, Anderson WC, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7(302):302ra136.
  15. Wang J, Anderson MG, Oleksijew A, et al. ABBV-399, a c-Met antibody-drug conjugate that targets both MET-amplified and c-Met-overexpressing tumors, irrespective of MET pathway dependence. Clin Cancer Res. 2017 Feb 15;23(4):992-1000.
  16. Phillips AC, Boghaert ER, Vaidya KS, et al. ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Mol Cancer Ther. 2016(4):661-669.
  17. Reynolds, PA, Smolen GA, Palmer RE, D, et al. Identification of a DNA-binding site and transcriptional target for the EWS-WT1(+KTS) oncoprotein. Genes Dev. 2003;17(17):2094-2107.
  18. Li Y, Hickson J, Ambrosi D, et al. ABT-165 is a first-in-class therapeutic dual variable domain immunoglobulin (DVD-IgTM) that targets DLL4 and VEGF for the treatment of cancer. Proceedings of the AACR, Part A: Abstracts 1-2696. 2016;57:abstract 867.